1. A therapeutic agent for a hernia of the intervertebral disc, which is characterized by the content of chondroitinase ABC as an active ingredient and is administered in such a way that the ingredient can be introduced into the human intervertebral disc in an amount of 1-5 units per intervertebral disc. The therapeutic agent according to claim 1, which is characterized by the content of chondroitinase ABC as an active ingredient and is administered so that the ingredient can be introduced into the human intervertebral disc in an amount of 1.25 units per intervertebral disc. The therapeutic agent according to claim 1, which is characterized by the content of chondroitinase ABC as an active ingredient and is administered so that the ingredient can be introduced into the human intervertebral disc in an amount of 2.5 units per intervertebral disc. The therapeutic agent according to claim 1, which is characterized by the content of chondroitinase ABC as an active ingredient and is administered so that the ingredient can be introduced into the human intervertebral disc in an amount of 5 units per intervertebral disc. The therapeutic agent according to any one of claims 1 to 4, wherein the therapeutic agent is an injection product. The therapeutic agent according to any one of claims 1 to 4, wherein the hernia of the intervertebral disc is a hernia of the intervertebral disc of the lumbar. The therapeutic agent according to claim 5, wherein the hernia of the intervertebral disc is a hernia of the intervertebral disc of the lumbar. The therapeutic agent according to any one of claims 1 to 4, wherein the chondroitinase ABC is derived from Proteus vulgaris. The therapeutic agent according to claim 5, wherein the chondroitinase ABC is derived from Proteus vulgaris. Composition1. Терапевтическое средство от грыжи межпозвоночного диска, которое характеризуется содержанием хондроитиназы ABC в качестве активного ингредиента и вводится таким образом, что ингредиент может быть введ
